Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

431 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-life use of oral disease-modifying treatments in Austria.
Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T; Austrian MS Treatment Registry (AMSTR). Guger M, et al. Among authors: enzinger c. Acta Neurol Scand. 2019 Jul;140(1):32-39. doi: 10.1111/ane.13097. Epub 2019 Apr 22. Acta Neurol Scand. 2019. PMID: 30958901 Free PMC article.
Apolipoprotein E epsilon 4 is associated with rapid progression of multiple sclerosis.
Fazekas F, Strasser-Fuchs S, Kollegger H, Berger T, Kristoferitsch W, Schmidt H, Enzinger C, Schiefermeier M, Schwarz C, Kornek B, Reindl M, Huber K, Grass R, Wimmer G, Vass K, Pfeiffer KH, Hartung HP, Schmidt R. Fazekas F, et al. Among authors: enzinger c. Neurology. 2001 Sep 11;57(5):853-7. doi: 10.1212/wnl.57.5.853. Neurology. 2001. PMID: 11552016 Clinical Trial.
Real-life clinical use of natalizumab and fingolimod in Austria.
Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T. Guger M, et al. Among authors: enzinger c. Acta Neurol Scand. 2018 Feb;137(2):181-187. doi: 10.1111/ane.12864. Epub 2017 Nov 20. Acta Neurol Scand. 2018. PMID: 29159801
Month-of-birth-effect in multiple sclerosis in Austria.
Walleczek NK, Frommlet F, Bsteh G, Eggers C, Rauschka H, Koppi S, Assar H, Ehling R, Birkl C, Salhofer-Polanyi S, Baumgartner A, Blechinger S, Buchinger D, Sellner J, Kraus J, Moser H, Mayr M, Guger M, Rathmaier S, Raber B, Liendl H, Hiller MS, Parigger S, Morgenstern G, Kempf I, Spiss HK, Meister B, Heine M, Cisar A, Bachler H, Khalil M, Fuchs S, Enzinger C, Fazekas F, Leutmezer F, Berger T, Kristoferitsch W, Aboulenein-Djamshidian F. Walleczek NK, et al. Among authors: enzinger c. Mult Scler. 2019 Dec;25(14):1870-1877. doi: 10.1177/1352458518810924. Epub 2018 Nov 22. Mult Scler. 2019. PMID: 30463473
Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.
Guger M, Enzinger C, Leutmezer F, Di Pauli F, Kraus J, Kalcher S, Kvas E, Berger T; Austrian MS Treatment Registry (AMSTR). Guger M, et al. Among authors: enzinger c. J Neurol. 2021 Nov;268(11):4303-4310. doi: 10.1007/s00415-021-10559-w. Epub 2021 Apr 22. J Neurol. 2021. PMID: 33890167 Free PMC article.
Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study.
Seifert-Held T, Eberhard K, Lechner C, Macher S, Hegen H, Moser T, Jacob GB, Puttinger G, Topakian R, Guger M, Kacar E, Zoche L, De Simoni D, Seiser A, Oberndorfer S, Baumgartner C, Struhal W, Zimprich F, Sellner J, Deisenhammer F, Enzinger C, Reindl M, Rauschka H, Berger T, Höftberger R. Seifert-Held T, et al. Among authors: enzinger c. Front Immunol. 2021 May 21;12:641106. doi: 10.3389/fimmu.2021.641106. eCollection 2021. Front Immunol. 2021. PMID: 34093529 Free PMC article.
431 results